GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is ...
Eligible patients can now get the Wegovy pill — the first oral GLP-1 treatment for weight management in adults — at Hy-Vee with a GoodRx discount.
GoodRx's telemedicine service offers oral semaglutide for weight loss, with initial pricing of $149 for 1.5 mg and 4 mg doses, increasing to $199 for 4 mg after April 2026. Larger doses of oral ...
GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy® End-to-end GLP-1 care done right: ...
Analysts have recently evaluated GoodRx Holdings and provided 12-month price targets. The average target is $4.16, accompanied by a high estimate of $6.00 and a low estimate of $2.75. This current ...
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is now available at a cash price of $149 per ...
Consumers can soon go to GoodRx for Weight Loss to determine eligibility and obtain a prescription for the first and only oral GLP-1 formulation GoodRx (Nasdaq: GDRX), the leading platform for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results